Welcome to our dedicated page for Orchestra BioMed Holdings SEC filings (Ticker: OBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Orchestra BioMed Holdings, Inc. filings document the governance, financing and material agreements of a biomedical company developing AVIM Therapy and Virtue SAB through strategic medical-device partnerships. Current reports describe revenue participation rights, strategic financing, distribution and right-of-first-refusal arrangements, underwritten common stock and pre-funded warrant offerings, investor presentations, and other business updates.
Proxy materials cover board elections, auditor ratification, executive compensation votes, equity and employee stock purchase plans, and related annual-meeting governance. The filing record also includes compensatory-arrangement disclosures for executive bonus plans, registration-statement references, exhibit filings and capital-structure disclosure tied to its cardiovascular product candidates.
Orchestra BioMed Holdings, Inc. Chief Financial Officer Andrew Taylor Lawrence reported a tax-related share withholding linked to restricted stock unit vesting. The issuer withheld 36,352 shares of common stock at an implied value of $4.02 per share to satisfy tax withholding obligations, and no shares were sold in the market. After this withholding, Lawrence directly holds 593,065 shares of Orchestra BioMed common stock.
Orchestra BioMed Holdings, Inc. director and officer David P. Hochman reported routine equity compensation activity tied to vesting of restricted stock units. On June 10, 2026, the issuer withheld a total of 6,566 shares of Common Stock at $4.02 per share to satisfy tax withholding obligations, with no shares sold in the market.
After these tax-withholding dispositions, Hochman holds 1,060,746 Common Stock shares directly and 436,199 shares indirectly through the DPH 2008 Trust, along with additional indirect holdings in several family trusts holding between 2,000 and 3,140 shares each.
Orchestra BioMed Holdings, Inc. director and officer David P. Hochman reported an open-market purchase of 5,000 shares of Common Stock on June 1, 2026 at a weighted average price of $3.83 per share. After this transaction, he directly holds 1,064,029 shares of Common Stock.
Additional shares are held indirectly through various family trusts, including 439,482 shares held by the DPH 2008 Trust and smaller positions held by several 2008 and 2019 family trusts.
Orchestra BioMed Holdings director and officer Darren Sherman reported selling 15,000 shares of common stock in an open-market transaction. The shares were sold at a weighted average price of $3.87 per share, in multiple trades between $3.81 and $4.01.
After this sale, Sherman directly holds 1,184,327 shares of Orchestra BioMed common stock. The filing notes that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 18, 2025, indicating the sales were scheduled in advance rather than timed discretionarily.
OBIO affiliate filed a Form 144 proposing the sale of 15,000 shares of Common Stock. The filing lists two tranches tied to restricted stock vesting: 12,196 shares dated 09/06/2024 and 2,804 shares dated 09/09/2024
The notice names Fidelity Brokerage Services LLC and indicates listing on NASDAQ; the filing date shown is 06/01/2026.
Orchestra BioMed Holdings, Inc. Chief Financial Officer Andrew Taylor Lawrence had 3,076 shares of common stock withheld at a price of $3.98 per share to cover tax obligations tied to vesting restricted stock units. No shares were sold in the market, and he now holds 629,417 shares directly.
Orchestra BioMed Holdings, Inc. director and officer Darren Sherman reported a tax-withholding share disposition tied to RSU vesting. On the transaction date, 4,925 shares of common stock were withheld by the company at $3.98 per share to satisfy tax obligations from vesting restricted stock units.
The footnote clarifies that no shares were sold in the market in connection with this event. After this routine tax-withholding transaction, Sherman directly holds 1,199,327 shares of Orchestra BioMed common stock.
Orchestra BioMed Holdings director Aryeh Jason made a small open-market purchase of company stock. On May 18, 2026, he bought 665 shares of common stock at a weighted average price of about $3.75–$3.76 per share. After this transaction, he directly owns 118,118 shares.
Orchestra BioMed Holdings director Jason Aryeh bought additional company stock in the open market. On May 15, 2026, he purchased 8,971 shares of common stock at a weighted average price of $3.90 per share, through multiple trades priced between $3.70 and $4.03.
Following this transaction, Aryeh directly owns 117,453 shares of Orchestra BioMed common stock. The filing notes that detailed trade-by-trade pricing within this range is available on request from the company, its shareholders, or the SEC staff.
Orchestra BioMed Holdings, Inc. director and officer David P. Hochman reported an open-market purchase of 5,000 shares of Common Stock on May 15, 2026 at a weighted average price of $3.77 per share. Following this purchase, he directly holds 1,059,029 shares of Common Stock.
The filing also lists indirect holdings through several family trusts, including 439,482 shares held by the DPH 2008 Trust and smaller positions held by the NSH 2008 Family Trust and three 2019 trusts.